

Special Issue

Biomarkers in Interventional Oncology

Message from the Guest Editors

Targeted minimally invasive procedures are being increasingly used in multimodality concepts of personalized cancer treatment. Interventional oncology applies thermal energy, radiation, or local delivery of chemotherapeutic agents at a high dosage directly into the tumor under image guidance in order to treat cancer more effectively. Interventional oncology plays an increasing role and is now considered the fourth pillar of oncology particularly for oligometastases where patients with limited metastatic disease are still considered curable. Response assessment of those minimally invasive therapies is nevertheless limited. Traditional imaging criteria, such as the response evaluation criteria in solid tumors (RECIST), frequently fail to assess, in a timely manner, the effect of minimally invasive cancer treatment. Liquid biopsies (i.e., blood analyses) can greatly supplement response assessment by non-invasively providing very specific biomarkers of tumor biology and its spread, or response to treatment. The role of biomarkers to gauge the response to minimally invasive tumor treatments is the primary topic of this Special Issue.

Guest Editors

Dr. Marianna Alunni-Fabroni

Prof. Dr. Moritz Wildgruber

Prof. S. Nahum Goldberg

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/65445

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)